Tetra Radar · FDA Approvals · Decision date
infigratinib: FDA decision date
BridgeBio Pharma, Inc. (BBIO) · 4 February 2027
The FDA accepted our NDA for filing, granted Priority Review and assigned a PDUFA target action date of February 4, 2027, for infigratinib.
Source: 10-Q of 29 October 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.